Wells Fargo’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wells Fargo’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-622,500	Closed	-$54.4M	–	6942
2024 Q1	$54.4M	Buy	+622,500	New	+$55.7M	0.01%	722
2023 Q2	–	Sell	-112,400	Closed	-$10.9M	–	7593
2023 Q1	$10.9M	Sell	112,400 -5,200	-4%	-$539K	﹤0.01%	1525
2022 Q4	$12.2M	Hold	117,600	–	–	﹤0.01%	1413
2022 Q3	$9.97M	Hold	117,600	–	–	﹤0.01%	1524
2022 Q2	$9.75M	Hold	117,600	–	–	﹤0.01%	1593
2022 Q1	$9.07M	Sell	117,600 -22,200	-16%	-$1.86M	﹤0.01%	1920
2021 Q4	$12.4M	Buy	139,800 +62,600	+81%	+$5.17M	﹤0.01%	1691
2021 Q3	$5.97M	Buy	77,200 +30,000	+64%	+$2.37M	﹤0.01%	2668
2021 Q2	$3.94M	Buy	+47,200	New	+$3.74M	﹤0.01%	3072
2021 Q1	–	Sell	-26,700	Closed	-$63K	–	6895
2020 Q4	$63K	Buy	26,700 +8,600	+48%	+$682K	﹤0.01%	5520
2020 Q3	$86K	Hold	18,100	–	–	﹤0.01%	5320
2020 Q2	$32K	Hold	18,100	–	–	﹤0.01%	5592
2020 Q1	$148K	Hold	18,100	–	–	﹤0.01%	4860
2019 Q4	$121K	Hold	18,100	–	–	﹤0.01%	5208
2019 Q3	$217K	Buy	+18,100	New	+$1.39M	﹤0.01%	4913

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's BMRN Position: Q1 2026 in Review

Wells Fargo increased its BioMarin Pharmaceuticals (BMRN) stake by 6.7% in Q1 2026, buying an estimated $124K and bringing the position to 33,775 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

Wells Fargo first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $272M in Q4 2015. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Wells Fargo held 33,775 shares of BioMarin Pharmaceuticals worth $1.91M as of Q1 2026.
Wells Fargo bought 2,119 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $124K.
BioMarin Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3309 holding.
Wells Fargo first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Wells Fargo's BioMarin Pharmaceuticals position peaked at $272M in Q4 2015.
555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.